SCHEMBL801792 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	USP1	O94782	13/20	0.56

▸	WDR48	Q8TAF3	13/20	0.56

▸	CYP1A2	P05177	8/20	0.55

▸	CYP2C19	P33261	7/20	0.55

▸	CYP2D6	P10635	6/20	0.55

▸	CYP3A4	P08684	6/20	0.55

▸	TSHR	P16473	4/20	0.55

▸	MEN1	O00255	3/20	0.55

▸	KMT2A	Q03164	3/20	0.55

▸	HSD17B10	Q99714	2/20	0.55

▸	ALDH1A1	P00352	2/20	0.55

▸	LMNA	P02545	2/20	0.55

▸	KDM4E	B2RXH2	1/20	0.55

▸	TP53	P04637	1/20	0.55

▸	MAPT	P10636	1/20	0.55

▸	CYP2C9	P11712	1/20	0.55

▸	HPGD	P15428	1/20	0.55

▸	RECQL	P46063	1/20	0.55

▸	CLK4	Q9HAZ1	2/20	0.51

▸	USP2	O75604	3/20	0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL10267502	0.88	USP1 (0.58)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL802393	0.85	CYP1A2 (0.59)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL13107373	0.85	GSK3A (0.46)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL802788	0.84	CYP1A2 (0.57)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL802787	0.82	GSK3A (0.67)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL802392	0.82	CYP1A2 (0.60)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL802200	0.81	CYP1A2 (0.59)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL801809	0.79	CYP1A2 (0.60)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL802451	0.77	CYP1A2 (0.61)	USP1WDR48CYP1A2CYP2C19CYP2D6
SCHEMBL801787	0.77	USP1 (0.56)	USP1WDR48CYP1A2CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-8633210-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
US-8633210-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
US-8524720-B2	Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2013-09-03	—	—	US	disclosed
US-8524720-B2	Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2013-09-03	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-7951820-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-05-31	—	—	US	disclosed
US-7951820-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-05-31	—	—	US	disclosed
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-10-07	—	—	US	disclosed
US-7691853-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-04-06	—	—	US	disclosed
US-7691853-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-04-06	—	—	US	disclosed
US-7473691-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-01-06	—	—	US	disclosed
US-7473691-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-01-06	—	—	US	disclosed
US-7390815-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2008-06-24	—	—	US	disclosed
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED	2007-11-22	—	—	US	disclosed
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED	2007-11-22	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	GSK3B, CDK3, GSK3A	USP1 3754/4885WDR48 1820/4885CYP1A2 1818/4885
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	GSK3B, GSK3A, CDK19	USP1 3070/4885WDR48 1491/4885CYP1A2 3042/4885
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	GSK3B, CDK3, GSK3A	USP1 3754/4885WDR48 1820/4885CYP1A2 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.